Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192.
View in:
PubMed
subject areas
Antineoplastic Combined Chemotherapy Protocols
Drug Discovery
Drugs, Investigational
Humans
Leukemia, Myeloid, Acute
Molecular Targeted Therapy
Remission Induction
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
authors with profiles
Wendy Stock